

Highly drug-resistant Salmonella enterica serotype Kentucky ST198-X1: a microbiological study

Simon Le Hello, Dorothée Harrois, Brahim Bouchrif, Lucile Sontag, Dalèle Elhani, Véronique Guibert, Khalid Zerouali, François-Xavier Weill

▶ To cite this version:

Simon Le Hello, Dorothée Harrois, Brahim Bouchrif, Lucile Sontag, Dalèle Elhani, et al.. Highly drug-resistant Salmonella enterica serotype Kentucky ST198-X1: a microbiological study. The Lancet Infectious Diseases, 2013, 13 (8), pp.672-679. 10.1016/S1473-3099(13)70124-5. pasteur-01109890

HAL Id: pasteur-01109890 https://pasteur.hal.science/pasteur-01109890

Submitted on 12 Mar 2019 $\,$

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

1	Highly drug-resistant Salmonella Kentucky ST198-X1 in the Mediterranean basin: a
2	microbiological study
3	
4	Simon Le Hello, Pharm.D ¹ , Dorothée Harrois, Pharm.D ¹ , Brahim Bouchrif Ph.D ² , Lucile Sontag ¹ , Dalèle Elhani
5	Ph.D ¹ , Véronique Guibert ¹ , Khalid Zerouali M.D ³ , François-Xavier Weill, M.D ^{1*}
6	
7	¹ Institut Pasteur, Unité des Bactéries Pathogènes Entériques, Centre National de Référence des Escherichia coli,
8	Shigella et Salmonella, WHO Collaborating Centre for Reference and Research on Salmonella, Paris, France.
9	² Sécurité Alimentaire et Environnement, Institut Pasteur du Maroc, Casablanca, Morocco.
10	³ Laboratoire de Microbiologie, CHU Ibn Rochd, Casablanca, Morocco.
11	
12	
13	*Corresponding author
14	François-Xavier Weill: Centre National de Référence des Escherichia coli, Shigella et Salmonella,
15	Unité des Bactéries Pathogènes Entériques, Institut Pasteur, 28 rue du docteur Roux, 75724 Paris
16	cedex 15. Tel: +33-1 45 68 83 45, Fax: +33-1 45 68 88 37. E-mail: francois-xavier.weill@pasteur.fr
17	
18	Running title: Highly drug-resistant Salmonella Kentucky
19	
20	Keywords: Salmonella Kentucky, multidrug resistance, fluoroquinolones, extended-spectrum
21	cephalosporins, cephalosporinase, extended-spectrum beta-lactamase, carbapenemase, antimicrobial
22	resistance, emergence
23	
24	Word count: 2915; one figure, three tables, one box (280 words), 30 references.
25	
26	

27 **SUMMARY (253)**

28 Background

29 Salmonella is a major food-borne pathogen found worldwide, which can cause life-

30 threatening infections. Ciprofloxacin and extended-spectrum cephalosporins (ESCs) are the

- 31 drugs of choice for severe Salmonella infections. We previously reported a ciprofloxacin-
- 32 resistant *S. enterica* serotype Kentucky strain (*Salmonella* Kentucky ST198-X1 CIP^R) that

and throughout Africa and the Middle East from 2002 to 2008.

34

35 Methods

36 Data for Salmonella Kentucky collected by the French national Salmonella laboratory

37 surveillance system from 2000 to 2011 and by two sites in Casablanca, Morocco, from 2003

38 to 2011 were analysed. Isolates displaying resistance to ESCs and/or with decreased

39 susceptibility to carbapenems were studied by *Xba*I pulsed-field gel electrophoresis and by

40 multilocus sequence typing. The mechanisms of resistance to antimicrobial drugs were

41 identified.

42

43 Findings

44 Isolations of *Salmonella* Kentucky ST198-X1 CIP^R have recently increased in frequency (376

45 isolates for 2009-2011 versus 200 for 2000-2008) in France, and the geographic area in which

46 infections occur has expanded to include the Indian subcontinent and South-East Asia. We

47 have observed multiple acquisitions of extended-spectrum β -lactamase (CTX-M-1, CTX-M-

48 15), plasmid-encoded cephalosporinase (CMY-2), or carbapenemase (OXA-48, VIM-2) genes

49 by *Salmonella* Kentucky ST198-X1 CIP^R isolates from the Mediterranean area since 2009.

50 Many of these highly drug-resistant *Salmonella* isolates are also resistant to most

51 aminoglycosides (*armA* gene) and to azithromycin (*mph*(*A*) gene).

52 **Panel: Research in context**

53

54 Systematic review

55 We searched PubMed for articles published up to January 30, 2013, with the search terms "Salmonella" and "carbapenemases" or "carbapenems" or "NDM-1". No language 56 57 restrictions were used. We identified only five studies describing various sporadic Salmonella 58 spp. isolates resistant to carbapenems. None of these isolates was also resistant to 59 fluoroquinolones. Two of these studies concerned isolates resistant to carbapenems due to mechanisms other than carbapenemase production: two clinical isolates of serotype Wien, 60 61 which had lost a porin and produced cephamycinase CMY-4, in Tunisia in 2001, and one 62 clinical isolate of serotype Typhimurium, which had lost two porins and produced cephamycinase CMY-2, in Taiwan in 2010.^{20,21} The first carbapenemase producer was a 63 64 clinical isolate of serotype Cubana, which produced carbapenemase KPC-2 and was obtained in the US in 1998.^{22,23} In 2011 and 2012, the first two clinical isolates of NDM-1-producing 65 Salmonella of serotypes Senftenberg and Westhampton were reported, isolated from patients 66 returning from India.^{24,25} In 2012, the first carbapenemase (VIM-1)-producing S. enterica 67 isolates were isolated from food animals in Europe.²⁶ 68

69

70 Interpretation

This report confirms the emergence of highly drug-resistant *Salmonella* Kentucky, a potential
risk to Public Health, in the Mediterranean basin. This ciprofloxacin-resistant *Salmonella*Kentucky ST198-X1 strain, which is increasingly frequently isolated, has recently acquired βlactamases (CTX-M ESBLs, CMY-2 AmpC, and VIM-2 and OXA-48 carbapenemases)
encoding resistance to extended-spectrum cephalosporins and carbapenems. Further efforts
are required from national and international health, food and agricultural authorities, to

- control the spread of this highly drug-resistant strain in humans and food animals. We
- 78 propose the inclusion of ciprofloxacin-resistant *Salmonella* Kentucky as a new target strain, in
- 79 national programmes for the control of *Salmonella* in poultry.
- 80

81 Funding

- 82 Institut Pasteur, Institut de Veille Sanitaire, "Fondation pour la Recherche Médicale" (DH),
- 83 the French Government "Investissement d'Avenir" programme.

84

86 **Box**

On October 14th 2009, a 69-year-old woman living in western France was hospitalised for an 87 88 upper respiratory tract infection, fever and diarrhoea. The symptoms began during a holiday in Egypt (September 19th to October 2nd, 2009). The patient's clinical history included a high-89 90 grade follicular lymphoma in 2003, treated by chemotherapy and allogeneic transplantation, 91 in remission since 2005. The patient had had repetitive respiratory infections due to sequellar 92 hypogammaglobulinaemia. Her last hospital admission was for right hemicolectomy surgery 93 in 2007. One day after admission, a S. enterica serotype Saintpaul isolate that was resistant to 94 ampicillin, susceptible to ESCs and had intermediate resistance to imipemem (MIC 3 mg/L) 95 was obtained from blood and stool cultures (Tables 2 & 3). Treatment with 1 g/day 96 ciprofloxacin was administered for 10 days. The patient was given a blood transfusion (two 97 units) and an intravenous polyclonal immunoglobulin perfusion and rapidly recovered. One 98 month later, the patient presented a new episode of febrile bronchial and diarrhoeal infection, 99 which was treated with 1 g/d ceftriaxone for five days. No bacteriological testing was 100 performed and the patient recovered slowly, with persistent digestive disorders. A new stool culture was performed on December 16th 2009, and was positive for *Salmonella* Kentucky 101 CIP^R, resistant to ESCs, cotrimoxazole and azithromycin, but susceptible to imipenem 102 103 (Tables 2 & 3). No antimicrobial agents were given, but a series of stool samples was 104 collected over time and cultured, to follow the elimination of the Salmonella strains. Salmonella Kentucky CIP^R was isolated in January 2010 and January 2011(Tables 2 & 3); 105 106 additional stool cultures for Salmonella in March and April 2011 were also positive (isolates 107 not sent to FNRC-Salm), despite the patient being free from digestive disorders. 108

110 INTRODUCTION

111 Antimicrobial drug-resistant bacteria are a serious challenge for the clinical care of patients and for Public Health in the 21st century.¹ The Gram-negative "superbugs", such as those 112 resistant to extended-spectrum cephalosporins (ESCs) due to the production of either 113 114 extended-spectrum β-lactamases (ESBLs) or cephamycinases (AmpC), seem to have now 115 eclipsed Gram-positive "superbugs" (i.e., methicillin-resistant Staphylococcus aureus and 116 vancomycin-resistant Enterococcus spp). Furthermore, the recent emergence of 117 Enterobacteriaeceae resistant to all β-lactam antibiotics, including ESCs and carbapenems, is 118 of particular concern, because carbapenems are, in many cases the last option available for 119 treating serious infection with ESC-resistant Gram-negative bacteria. Indeed, the development 120 pipeline for new antimicrobial drugs with bactericidal activity against Gram-negative bacteria has now run dry.^{2,3} 121

122

123 In a 2004 report entitled "Bad Bugs, No Drugs", the Infectious Diseases Society of America 124 (IDSA) imagined a catastrophic scenario with an explosive epidemic of 220,000 cases and 125 1,730 deaths caused by a multidrug-resistant non-typhoidal Salmonella, resistant, in 126 particular, to both ESCs and fluoroquinolones. This choice was based on the following 127 observations (i) Salmonella is a prevalent zoonotic agent causing an estimated 1.7 million 128 infections, resulting in 2,800 deaths per year in high-income regions of North America in 2006,⁴ (ii) Salmonella can cause major food-borne outbreaks, such as that in the US in 1994 129 130 associated with manufactured ice cream contaminated with Salmonella enterica serotype Enteritidis, which caused sickness in an estimated 224,000 people,⁵ (iii) fluoroquinolones, 131 132 including ciprofloxacin, and ESCs are the drugs of choice for treating severe Salmonella 133 infections and for people at risk of such infections (infants, the elderly and

immunocompromised patients), and (iv) infections with drug-resistant *Salmonella* are
associated with higher morbidity and mortality.⁶

136

137 We previously reported the international emergence of a multidrug-resistant S. enterica 138 serotype Kentucky (Salmonella Kentucky) strain, identified as being multilocus sequence 139 type (MLST) ST198 and as belonging to XbaI pulsed-field gel electrophoresis (PFGE) cluster X1.⁷ Salmonella Kentucky ST198-X1 isolates were resistant to several antimicrobial drugs, 140 141 including ciprofloxacin (minimal inhibitory concentration $[MIC] \ge 4 \text{ mg/L}$), which is a very unusual resistance trait in Salmonella.^{8,9} The first ciprofloxacin-resistant Salmonella 142 Kentucky (Salmonella Kentucky CIP^R) to be identified was isolated from a French tourist 143 144 who visited Egypt in 2002. From then until 2008, the Salmonella surveillance systems in 145 France, England, and Denmark detected 489 cases of infection with this strain in people who had travelled to or stayed in Africa or the Middle East.⁷ Hospitalisation was more frequent 146 among patients infected with CIP^R Kentucky (mean age, 36 years) than among those infected 147 with Kentucky strains susceptible to ciprofloxacin.⁷ 148 149 All Salmonella Kentucky CIP^R isolates in our survey were susceptible to ESCs. However, one 150 case report described a Belgian traveller infected with *Salmonella* Kentucky CIP^R during a 151 152 trip to Libya in 2005, who required treatment with meropenem due to ESC resistance (CTX-M-1 ESBL production) after multiple treatment failures for a severe infection.¹⁰ 153 154 The aim of this study was to monitor recent trends in the global epidemiology and antimicrobial resistance of the Salmonella Kentucky ST198-X1 CIP^R strain. The work was 155 156 conducted in parallel in France, where this infection occurred mostly in travellers or migrants, 157 and in Morocco, where most of the French travellers or migrants had acquired the infection.

- 158 This study identified highly drug-resistant (HDR) isolates, present in both France and
- 159 Morocco since 2009. These CIP^R isolates acquired in the Mediterranean area produce various
- 160 carbapenemases, cephamycinase, or ESBLs. This report indicates that *Salmonella* has taken a
- 161 major step towards panresistance and suggests that the catastrophic scenario imagined by the
- 162 IDSA might become all too real in the near future.

164 MATERIALS & METHODS

165

166 Data for human Salmonella infections

- 167 France
- 168 We used data from the French National Reference Centre for Salmonella (FNRC-Salm),

169 established since 1947. During the 2000s, the FNRC-Salm network included a stable number

170 of approximately 1,400 hospital and private clinical laboratories. In 2008, an unpublished

171 survey of all French clinical laboratories (n=3,375, response rate of 95%) estimated that about

172 65% of all human *Salmonella* isolates in France were reported to the FNRC-Salm. Basic

173 epidemiological data (date and site of isolation, sex and age of the patient, and international

travel) were recorded for each isolate. From 2000 to 2011, 128,836 serotyped Salmonella

175 isolates were registered at the FNRC-Salm, including 954 non-repeated Salmonella Kentucky

176 isolates (0.7% of all *Salmonella* isolates).

177

178 Morocco

We used 2003-2011 data from two sites in Casablanca, the largest city in Morocco. The first
site was the Microbiology Laboratory of the University Hospital Centre Ibn Rochd (UHCIR),
Casablanca, a 1,700-bed teaching hospital. The second site was the Pasteur Institute of
Morocco (PIM), which receive clinical strains of *Salmonella* for serotyping from private
laboratories. Between 2003 and 2011, 226 *Salmonella* isolates were obtained and serotyped,
including 30 non-repeated *Salmonella* Kentucky isolates (12.8% of all *Salmonella* isolates).

186 Microbiological investigations

187 Bacterial isolates

All but two (which could not be subcultured) of the 954 *Salmonella* Kentucky isolates
obtained from humans between 2000 and 2011 in France were included in this study. Thirty
(26 from UHCIR and 4 from PIM) *Salmonella* Kentucky isolates collected from humans in
Casablanca, Morocco between 2003 and 2011 were also studied. One additional isolate from
the FNRC-Salm was studied: one of serotype Saintpaul isolated from a patient co-infected
with *Salmonella* Kentucky in 2009.

194

195 Antimicrobial susceptibility testing

196 Antimicrobial susceptibility testing (AST) was performed on all *Salmonella* isolates, by the

197 disk diffusion method with a panel of 32 antimicrobial agents (Bio-Rad, Marnes-La-Coquette,

198 France).⁷ The MICs of ceftriaxone, ceftazidime, imipenem, ertapenem, meropenem,

199 ciprofloxacin, azithromycin, colistin, and tigecycline were determined by Etests (AB Biodisk,

200 Solna, Sweden). Results were interpreted with the Antibiogram Committee of the French

201 Society for Microbiology (CA-SFM) (<u>www.sfm-microbiologie.org/</u>) breakpoints. In

202 particular, susceptible isolates were defined as having a MIC ≤ 0.5 mg/L for ciprofloxacin,

and resistant isolates were defined as having a MIC > 1 mg/L for ciprofloxacin, regardless of

204 isolate source (i.e., intestinal or extraintestinal). Isolates were defined as highly drug-resistant

205 if they were resistant to at least four antibiotic classes, including both fluoroquinolones (i.e.,

206 ciprofloxacin) and ESCs (i.e., ceftriaxone and/or ceftazidime).

207

208 Molecular typing

209 PulseNet standard pulsed-field gel electrophoresis (PFGE) of XbaI-digested chromosomal

210 DNA and multilocus sequence typing (MLST) were performed as previously described.⁷

211

²¹² Determination of resistance mechanisms

213	The presence of beta-lactam resistance genes (bla_{TEM} , bla_{SHV} , $bla_{\text{OXA-1}}$ group, bla_{CMY} , $bla_{\text{CTX-}}$
214	_M , bla_{OXA-48} , bla_{VIM} , bla_{NDM} , and bla_{KPC}), plasmid-mediated quinolone resistance genes, (qnrA,
215	qnrB, qnrS, qnrD, aacA4-cr (also known as aac(6')-Ib-cr) and qepA), macrolide resistance
216	genes (ermA, ermB, ermC, mph(A), ereA, ereB, mrsA, mrsB, mefA, and mefE),
217	aminoglycoside resistance genes (armA, rmtA, rmtB, rmtC, rmtD, and npmA), class 1 integron
218	gene cassettes and Salmonella genomic island 1 (SGI1) was assessed by PCR, as previously
219	described. ^{7,11-14}
220	
221	The quinolone resistance-determining region (QRDR) of gyrA, gyrB, parC and parE
222	(encoding subunits of the DNA gyrase and the topoisomerase IV) was sequenced, as
223	previously described. ⁷ The nucleotide and deduced amino-acid sequences were analysed and
224	compared with sequences available from the National Center for Biotechnology Information
225	website (<u>http://www.ncbi.nlm.nih.gov</u>).

We assessed resistance transfer by mating, with ESBL, cephamycinase and carbapenemase producers, using liquid and solid media, with *E. coli* K-12 BM14 resistant to sodium azide as the recipient strain. Transconjugants were selected on Drigalski agar (Bio-Rad) supplemented with ceftriaxone (4 mg/L), ceftazidime (16 mg/L), or imipenem (3 mg/L) plus sodium azide (500 mg/L). Three *E. coli* transconjugants were arbitrarily selected in each experiment. We used S1 nuclease treatment and PFGE to determine the sizes of bacterial plasmids accurately, and PCR-based replicon typing analysis was performed, as previously described.¹⁵

235 **RESULTS**

236

237 Occurrence of Salmonella Kentucky CIP^R in humans

238 France

239 Of the 497 isolates of *Salmonella* Kentucky obtained in France between 2000 and 2008, 200

240 (40.2%) were resistant to ciprofloxacin (previously reported in reference 7). For the period

241 2009-2011, 376 (82.6%) of the 455 *Salmonella* Kentucky tested were CIP^R (Figure). This

242 near doubling of the number of *Salmonella* Kentucky CIP^R isolates obtained, in a third of the

time, with a stable network of laboratories, against a backdrop of a general decrease in the

number of isolations of *Salmonella* (\approx 11,000 clinical isolates received per year during the

245 period 2000-2008 vs \approx 10,000 during the period 2009-2011), indicates that this *Salmonella*

246 Kentucky CIP^R strain continued to circulate and spread.

247

Travel information was available for 371 patients (64.5%) infected with CIP^R Kentucky
during the period 2000-2011 (Table 1). Of these 371 patients, 338 (91.1%) had travelled
internationally in the 15 days before the onset of illness, whereas the remaining 33 patients
had not. Most of the patients seen between 2002 and 2005 had travelled to North-East or East
Africa. Since 2006, patients have been reporting travel to North-East and East Africa, North
Africa, West Africa, and the Middle East. Since 2009, the area of infection has extended to
include India.

- 255
- 256
- 257

258 Morocco

259 Of the 30 clinical isolates of Salmonella Kentucky obtained in Casablanca between 2003 and

260 2011, 19 (63.3%) were CIP^R. The first *Salmonella* Kentucky CIP^R isolate was obtained in

261 2006 and the annual number of isolates obtained has since fluctuated between one and eight

262 (2007, *n*=1; 2008, *n*=5; 2009, *n*=2; 2010, *n*=8; 2011, *n*=2).

263

264 Recent trends in the antimicrobial resistance of Salmonella Kentucky

265 Emergence of CIP^{R} -ESC^R Salmonella Kentucky in the Mediterranean area since 2009

266 Based on the FNRC-Salm 2000-2011 data, the first Salmonella Kentucky isolate resistant to

267 ESCs (ESC^R) was isolated in 2009 (Figure). From 2009 to 2011, 10 *Salmonella* Kentucky

268 ESC^R isolates (2.2% of all *Salmonella* Kentucky during this period) in total were identified:

six were susceptible to ciprofloxacin and had a cephamycinase-like profile and four were

270 resistant to both ciprofloxacin and ESCs. The four CIP^{R} -ESC^R isolates were acquired in

271 Algeria, Morocco, Egypt, and Turkey (Tables 2 & 3). They produced the cephamycinase

272 CMY-2 (*n*=2) or the ESBLs CTX-M-1 (*n*=1) or CTX-M-15 (*n*=1), encoded by 90 to 200 kb

273 plasmids from the IncI1, IncL/M or IncA/C incompatibility groups.

274

275 Two Salmonella strains producing carbapenemase OXA-48 in a traveller returning from
276 Egypt in 2009

277 One of the four *Salmonella* Kentucky CIP^R-ESC^R isolates detected since 2009, #09-9322 (see

278 previous section), was isolated from a patient co-infected with another serotype of

279 Salmonella, Saintpaul, which produced a carbapenamase not present in #09-9322, but

subsequently found in one of the three sequential *Salmonella* Kentucky isolates from the same

281 patient (box and Tables 2 & 3). The serotype Saintpaul isolate was found to contain the

282 *bla*_{OXA-48} carbapenemase gene on an IncL/M plasmid of about 70 kb. The three sequential

Salmonella Kentucky CIP^R isolates belonged to the ST198-X1 strain, and carried the gyrA 283 284 and *parC* mutations previously encountered in Kentucky isolates from Egypt and West Africa.⁷ The three isolates also contained the phosphotransferase mph(A) gene conferring 285 286 high-level resistance to azithromycin. The three isolates presented different resistance 287 profiles, due to the acquisition/loss of various R plasmids and also, probably, due to IS26 rearrangements of the SGI1.⁷ The first isolate was resistant to ESCs due to the presence of the 288 289 *bla*_{CMY-2} gene, whereas the most recent isolate, collected one year later, contained the *bla*_{OXA-} 290 48 carbapenemase gene. All four isolates were susceptible to colistin and tigecycline.

291

292 Highly drug-resistant Salmonella Kentucky isolates producing VIM-2 in Morocco in 2010

293 Five of the 30 Salmonella Kentucky isolates obtained in Casablanca, Morocco, between 2003

and 2011 (16.6%) were ESC^{R} . These five *Salmonella* Kentucky ST198-X1 ESC^{R} -CIP^R

isolates had decreased susceptibility to imipenem (MIC range, 1-3 mg/L). They all contained

296 the bla_{VIM-2} gene within In58,¹⁶ itself carried on a 30-kb plasmid. Three isolates originated

297 from patients hospitalised in three different reanimation wards (one blood culture, two urine

cultures) of the UHCIR during January 2010, the other two isolates being obtained from stool

cultures performed at the PIM in January and August 2010.

300

302 **DISCUSSION**

303 We report a new step towards pan-antimicrobial resistance in Salmonella, a major foodborne 304 pathogen found worldwide, which can cause life-threatening infections. The Salmonella 305 Kentucky ST198-X1 isolates reported here are resistant to both fluoroquinolones and ESCs 306 (except for the OXA-48-producing strain), and some also display full or intermediate 307 resistance to carbapenems. Many are also resistant to most aminoglycosides (armA gene) and 308 to azithromycin (*mph*(*A*) gene). Salmonella Kentucky ST198-X1 is a particularly successful 309 strain that has accumulated various chromosomal resistance determinants since the mid-310 1990s, with the integration of the Salmonella genomic island 1 (encoding resistance to 311 multiple antimicrobial drugs, including amoxicillin, gentamicin, and sulfonamides), followed 312 by cumulative mutations in the gyrA and parC genes, leading to resistance to nalidixic acid, and then to ciprofloxacin, in 2002. This strain was mostly identified in Egypt before 2005.⁷ 313 314 but has since spread rapidly throughout Africa and the Middle East. The slight decrease in isolation rates for this strain in 2011 probably resulted from the "Arab Spring", which may 315 have discouraged travel to the area in which this strain is endemic. Thus, 150 Salmonella 316 Kentucky CIP^R isolates were obtained at the FNRC-Salm in 2012 (data not shown), a number 317 similar to that obtained in 2010. The Salmonella Kentucky CIP^R strain was first identified in 318 319 the Indian subcontinent in 2009, and a pattern of current spread across Asia is also suggested by the isolation of two Salmonella Kentucky CIP^R isolates from French patients reporting 320 travel to Vietnam and Indonesia in 2012 (data not shown). As the geographic spread of this 321 322 strain has been predicted by a French surveillance system, it may be partially biased by the 323 preferred destinations of French travellers and particular migrant populations with historical 324 links to France. Where possible, these data should be confirmed by local studies.

325

326 This epidemic was previously associated with a livestock (autochthonous poultry) reservoir of this Salmonella Kentucky CIP^R strain in Africa. It was suggested that the common use of 327 328 fluoroquinolones in poultry and the lack of both laboratory-based surveillance of infections 329 and control measures in the countries in which this strain circulates played a role in the rapid spread of this strain after 2002.⁷ A survey performed on 92 poultry farms in Sudan, East 330 331 Africa, in 2008 revealed that enrofloxacin, a fluoroquinolone, was commonly added to the drinking water on 14% of the farms surveyed.¹⁷ Both here and in our previous study, ~11% of 332 333 the patients reported no history of travel outside Europe, suggesting that these infections may 334 have resulted from the consumption of contaminated foods or secondary contamination in Europe. Indeed, contaminated spices from North Africa have previously been identified in 335 France and the US.⁷ This strain also seems to have become established in some European 336 flocks, another major source of concern. In 2010, Salmonella Kentucky CIP^R isolates were 337 found in turkey meat products in Germany and in turkey meat or flocks in Poland.^{18,19} One of 338 the Salmonella Kentucky CIP^R isolates recovered from a flock in Poland in 2010 was also 339 resistant to ESCs, due to the production of a CTX-M ESBL.¹⁹ 340 341

The diversity of the recently acquired β-lactamases (CTX-M ESBLs, CMY-2 AmpC, and
VIM-2 and OXA-48 carbapenemases) suggests that the increasingly common *Salmonella*Kentucky ST198-X1 CIP^R strain has been "collecting" genes for resistance to ESCs and
carbapenems. Resistance to carbapenems is otherwise extremely rare in *Salmonella* spp.
(panel). The simultaneous presence of ESCs and carbapenem determinants (CMY-2 and
OXA-48) was even documented in this study in *Salmonella* Kentucky ST198-X1 CIP^R
isolated from a single patient.

349

350 A similar scenario, but without the acquisition of carbapenemase, occurred in Taiwan for S. enterica serotype Choleraesuis (Salmonella Choleraesuis), a serotype acquired from pigs and 351 associated with extraintestinal infection in humans.⁸ The first CIP^R isolates appeared in 2000 352 and, in the third quarter of 2001, 60% of the Salmonella Choleraesuis isolates from humans 353 were CIP^{R.8} This trait was attributed to the use of enrofloxacin in pigs. Additional resistance 354 to ESCs mediated by the cephamycinase CMY-2 has appeared since 2002.²⁶ This enzyme is 355 356 frequent in many Salmonella serotypes, including Newport in the US, where its emergence 357 has been associated with the use of ceftiofur, an ESC licensed for use in cattle, pigs, and other food animals.²⁷ Unlike Salmonella Choleraesuis CIP^R and Newport ESC^R, Salmonella 358 Kentucky ST198-X1 CIP^R is not restricted to a single country or region, rendering control 359 360 measures in livestock more difficult.

361

362 We found that Salmonella Kentucky ST198-X1 had a broad geographic distribution, 363 overlapping with that of certain plasmid-borne carbapenemases, such as OXA-48 and VIM.^{12,16} This makes it likely that carbapenemase-producing Salmonella will become more 364 365 frequent in the Mediterranean area in the near future, particularly if such carbapenemase 366 producers become established in livestock, as previously observed for ESBL- and cephamycinase-producing Salmonella in industrialised countries.²⁷⁻²⁹ Indeed, isolation of the 367 368 VIM-1-producing S. enterica serotype Infantis from two pig farms and one poultry farm in Germany was reported in 2012.²⁵ 369

370

Another issue is the difficulty of phenotypic detection for several carbapenemase producers.¹²
This problem is particularly difficult for OXA-48, which weakly hydrolyses carbapenems but
not ESCs in the absence of additional ESBL and/or cephamycinase and permeability defects.
Indeed, carbapenem MICs were found to be low for the carbapenemase producers. Two

375	isolates, one OXA-48-positive and one VIM-2-positive Kentucky isolate, were even classified
376	as susceptible to the three carbapenems tested, on the basis of the CLSI or CA-SFM
377	breakpoints. The use of rapid diagnostic tests, such as the recently developed Carba NP test,
378	would facilitate the early detection of carbapenemase producers. ³⁰
379	
380	In conclusion, this report highlights the recent emergence of HDR Salmonella and the need to
381	screen Salmonella isolated either from humans or food-producing animals for carbapenemase
382	producers. The main types of carbapenemase (KPC, OXA-48, NDM, VIM) have now been
383	identified in Salmonella, and half of these enzymes have been found in the Salmonella
384	Kentucky ST198-X1 strain. National and international health, food and agricultural
385	authorities need to recognise rapidly the potential risk to Public Health posed by Salmonella
386	Kentucky ST198-X1 CIP ^R , so that Salmonella Kentucky CIP ^R can be included, as a new
387	targeted strain, in current national programmes for the control of Salmonella in poultry.
388	
389	AUTHOR CONTRIBUTIONS
390	
391	Conceived and designed the experiments: SLH and FXW. Performed the experiments: DH,
392	LS, DE, VG. Contributed reagents/materials/analysis tools: BB, KZ. Analysed the data: SLH
393	and FXW. Wrote the paper: SLH and FXW. Reviewed, critiqued and offered comments on
394	the text: DH, BB, KZ.
395	
396	ACKNOWLEDGEMENTS
397	
398	We thank Dr. Isabelle Loirat for providing clinical information and Mr. Erwan Trochu for
399	expert technical assistance. We thank all corresponding laboratories of the French National

400	Reference Centre for E. coli, Shigella, and Salmonella.
401	The French National Reference Centre for E. coli, Shigella, and Salmonella is funded by the
402	Institut Pasteur and the Institut de Veille Sanitaire. Dorothée Harrois was supported by a grant
403	from "La Fondation pour la Recherche Médicale". The "Unité des Bactéries Pathogènes
404	Entériques" belongs to the "Integrative Biology of Emerging Infectious Diseases" Laboratory
405	of Excellence funded by the French Government "Investissement d'Avenir" programme
406	(grant no. ANR-10-LABX-62-IBEID).
407	
408	
409	CONFLICTS OF INTEREST
410	All authors declare that they have no competing interests or conflicts of interest.
411	
412	REFERENCES
413	1. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st centurya clinical super-
414	challenge. N Engl J Med 2009; 360: 439-43.
415	2. Walsh TR. The emergence and implications of metallo- β -lactamases in Gram-negative
416	bacteria. Clin Microbiol Infect 2005; 11: 2-9.
417	3. Nordmann P, Poirel L, Walsh TR, Livermore DM. The emerging carbapenemases.
418	Trends Microbiol 2011; 18: 588-95.
419	4. Majowicz SE, Musto J, Scallan E, et al. The global burden of nontyphoidal
420	Salmonella gastroenteritis. Clin Infect Dis 2010; 50: 882-9.
421	5. Hennessy TW, Hedberg CW, Slutsker L, et al. A national outbreak of Salmonella
422	enteritidis infections from ice cream. The Investigation Team. N Engl J Med 1996;
423	334: 1281-6.
424	6. Mølbak K. Human health consequences of antimicrobial drug-resistant Salmonella
425	and other foodborne pathogens. Clin Infect Dis 2005; 41: 1613-20.

426	7.	Le Hello S, Hendriksen RS, Doublet B, et al. International spread of an epidemic
427		population of Salmonella enterica serotype Kentucky ST198 resistant to
428		ciprofloxacin. J Infect Dis 2011; 204: 675-84.
429	8.	Chiu CH, Wu TL, Su LH, et al. The emergence in Taiwan of fluoroquinolone
430		resistance in Salmonella enterica serotype Choleraesuis. N Engl J Med 2002; 346:
431		413-9.
432	9.	Olsen SJ, DeBess EE, McGivern TE, et al. A nosocomial outbreak of
433		fluoroquinolone-resistant Salmonella infection. N Engl J Med 2001; 344: 1572-9.
434	10.	Collard JM, Place S, Denis O, et al. Travel-acquired salmonellosis due to Salmonella
435		Kentucky resistant to ciprofloxacin, ceftriaxone and co-trimoxazole and associated
436		with treatment failure. J Antimicrob Chemother 2007; 60: 190-2.
437	11.	Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L. Detection of erythromycin-
438		resistant determinants by PCR. Antimicrob Agents Chemother 1996; 40: 2562-6.
439	12.	Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing
440		Enterobacteriaceae. Emerg Infect Dis 2011; 17: 1791-8.
441	13	Accou-Demartin M, Gaborieau V, Song Y, et al. Salmonella enterica serotype Typhi
442		with nonclassical quinolone resistance phenotype. <i>Emerg Infect Dis</i> 2011; 17: 1091-4.
443	14.	Fritsche TR, Castanheira M, Miller GH, et al. Detection of methyltransferases
444		conferring high-level resistance to aminoglycosides in Enterobacteriaceae from
445		Europe, North America, and Latin America. Antimicrobial Agents Chemother 2008;
446		52: 1843-5.
447	15.	Fabre L, Delauné A, Espié E, et al. Chromosomal integration of the extended-
448		spectrum beta-lactamase gene <i>bla</i> _{CTX-M-15} in <i>Salmonella enterica</i> serotype Concord
449		isolates from internationally adopted children. Antimicrob Agents Chemother 2009;
450		53: 1808-16.

- 451 16. Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace.
 452 *J Antimicrob Chemother* 2012; 67: 1597-606.
- 453 **17.** Sirdar MM, Picard J, Bisschop S, Gummow B. A questionnaire survey of poultry
 454 layer farmers in Khartoum State, Sudan, to study their antimicrobial awareness and
 455 usage patterns. *Onderstepoort J Vet Res* 2012; **79:** E1-8.
- 456 **18.** Beutlich J, Guerra B, Schroeter A, Arvand M, Szabo I, Helmuth R. [Highly
- 457 ciprofloxacin resistant *Salmonella enterica* serovar Kentucky isolates in turkey meat
 458 and a human patient] in German. *Berl Munch Tierarztl Wochenschr* 2012; **125**: 89-95.
- 459 **19.** Wasyl D, Hoszowski A. First isolation of ESBL-producing *Salmonella* and emergence
- 460 of multiresistant *Salmonella* Kentucky in turkey in Poland. *Food Research*
- 461 *International* 2012; **45**: 958-61
- 462 **20.** Armand-Lefèvre L, Leflon-Guibout V, Bredin J, et al. Imipenem resistance in
- 463 Salmonella enterica serovar Wien related to porin loss and CMY-4 β -lactamase

464 production. *Antimicrob Agents Chemother* 2003; **47:** 1165-8.

- 465 **21.** Miriagou V, Tzouvelekis LS, Rossiter S, Tzelepi E, Angulo FJ, Whichard JM.
- 466 Imipenem resistance in a *Salmonella* clinical strain due to plasmid-mediated class A
 467 carbapenemase KPC-2. *Antimicrob Agents Chemother* 2003; **47**: 1297-300.
- 468 22. Su LH, Wu TL, Chiu CH. Development of carbapenem resistance during therapy for
 469 non-typhoid *Salmonella* infection. *Clin Microbiol Infect* 2012; 18: E91-4.
- 470 **23.** Savard P, Gopinath R, Zhu W, et al. First NDM-positive *Salmonella* sp. strain
- 471 identified in the United States. *Antimicrob Agents Chemother* 2011; **55**: 5957-8.
- 472 **24.** Cabanes F, Lemant J, Picot S, et al. Emergence of *Klebsiella pneumoniae* and
- 473 *Salmonella* metallo- β-lactamase (NDM-1) producers on Reunion Island. *J Clin*
- 474 *Microbiol* 2012; **50**: 3812.

475	25. Fischer J, Rodríguez I, Schmoger S, et al. Salmonella enterica subsp. enterica
476	producing VIM-1 carbapenemase isolated from livestock farms. J Antimicrob
477	Chemother 2013; 68: 478-80.

- 478 26. Su LH, Teng WS, Chen CL, et al. Increasing ceftriaxone resistance in Salmonellae,
 479 Taiwan. *Emerg Infect Dis* 2011; 17: 1086-90.
- 480 **27.** Gupta A, Fontana J, Crowe C, et al. Emergence of multidrug-resistant *Salmonella*
- *enterica* serotype Newport infections resistant to expanded-spectrum cephalosporins
 in the United States. *J Infect Dis* 2003; **188**: 1707-16.
- 483 **28.** Rodríguez I, Barownick W, Helmuth R, et al. Extended-spectrum β -lactamases and
- 484 AmpC β-lactamases in ceftiofur-resistant *Salmonella enterica* isolates from food and
- 485 livestock obtained in Germany during 2003-07. *J Antimicrob Chemother* 2009; 64:
 486 301-9.
- 487 **29.** Bertrand S, Weill FX, Cloeckaert A, et al. Clonal emergence of extended-spectrum
- 488 beta-lactamase (CTX-M-2)-producing *Salmonella enterica* serovar Virchow isolates
- 489 with reduced susceptibilities to ciprofloxacin among poultry and humans in Belgium
- 490 and France (2000 to 2003). *J Clin Microbiol* 2006; **44:** 2897-903.
- 491 **30.** Nordmann P, Dortet L, Poirel L. Rapid detection of carbapenemase-producing
 492 Enterobacteriaceae. *Emerg Infect Dis* 2012; **18:** 1503-7.
- 493
- 494
- 495

- **Table 1**: Countries visited by patients infected with *S. enterica* serotype Kentucky resistant to
- 498 ciprofloxacin in the 15 days before the onset of illness (data from the French National

499 Reference Centre for *Salmonella*)

Country	2002-2005	2006-2008	2009-2011	Total
Africa				_
Not specified		3	2	5
Algeria		9	60	69 2
Cameroon		2	1	3
Djibouti		1	2	3
Egypt	11	11	7	29
Ethiopia			2	2
Ivory Coast			6	6
Kenya	2	1		3
Libya		2	1	3
Mauritania			2	2
Morocco		69	78	147
Senegal			7	7
Sudan	1			1
Tanzania	1	2		3
Tunisia		5	21	26
Middle East				
Iran		1		1
Iraq			1	1
Israel			1	1
Lebanon		2	2	4
Saudi Arabia		1		1
Syria			1	1
Turkey		2	2	4
Asia				
India			8	8
North America				
Canada			1	1
Europe				
France [†]		6	27	33
Croatia			1	1
Greece			1	1
Spain			5	5
Total	15	117	239	371

 [†]France is indicated as the country of infection in cases of notification of an absence of international travel for up to 2 months before the onset of symptoms

504 505 Table 2: Antimicrobial drug-resistant Salmonella isolates included in this study

~	\sim	~
_	0	~
- 5	()	6
	1,	U.

5																
Isolate Serotype		Date of	Source ^a	Country of		MLST/ PFGE	SGI1				MI	C (mg/l	L)°			
		isolation		infection												
								Cro	Caz	IMP	ETP	MEM	CIP	Azi	CST	TGC
Isolates reco	vered through	the French n	ational Salmonella s	urveillance	system											
09-8391	Kentucky	02 Nov 09	F, 65y, stool, H	Morocco	A Cro Caz Fox Nal CIP	ST198/X1e	+	64	48	0.38	0.064	0.064	32	8	0.25	0.5
09-9322	Kentucky	16 Dec 09	F, 70y, stool, N	Egypt	A Cro Caz Fox S Sp K T N Chl Sul Tmp Nal CIP Azi	ST198/X1w	+	24	64	0.5	0.023	0.047	12	128	0.19	0.38
10-0720	Kentucky	31 Jan 10	F, 25y, stool, H	Turkey	A Cro S Sp G Sul Te Nal CIP	ST198/X1b	+	64	4	0.25	0.016	0.064	16	4	0.25	1
10-5456	Kentucky	13 Aug 10	F, 7y, stool, H	Algeria	A Cro Caz S Sp K T N G Ak Chl Sul Tmp Nal Cip Azi	ST198/X1a	+	>256	>256	0.38	0.023	0.047	12	32	0.25	0.5
Isolates reco	vered through	the survey in	n Casablanca, Moroc	co												
10-1923	Kentucky	04 Jan 10	M, 25y, urine, H	Morocco	A Cro Caz Fox IMP* S Sp K T G Sul Te Nal CIP	ST198/X1j	+	256	192	3	1.5	0.25	12	4	0.25	1
10-1922	Kentucky	07 Jan 10	M, 20y, blood, H	Morocco	A Cro Caz Fox IMP* S Sp K T N G Ak Is Sul Te Nal CIP	ST198/X1m	+	24	24	3	0.5	0.25	12	6	0.25	1
10-1924	Kentucky	21 Jan 10	M, 92y, urine, H	Morocco	A Cro Caz Fox IMP* S Sp K T N G Sul Te Nal CIP	ST198/X1j	+	256	96	3	3	1	16	6	0.25	1
10-1925	Kentucky	24 Jan 10	M, >18y, stool, N	Morocco	A Cro Caz Fox S Sp K T N G Ak Is Sul Te Nal CIP	ST198/X1j	+	32	24	1	0.19	0.25	8	4	0.25	0.75
10-1926	Kentucky	25 Aug 10	M, >18y, stool, N	Morocco	A Cro Caz Fox IMP* S Sp K T G Sul Te Nal CIP	ST198/X1j	+	>256	48	2	0.75	1	8	4	0.5	1
Isolates reco	vered from a s	ingle patient	¢													
09-7981	Saintpaul	16 Oct 09	F, 69y, blood, H	Egypt	A IMP*	ST1670	-	1.5	2	3	1	1.5	0.023	2	0.25	0.38
10-0305	Kentucky	07 Jan 10	F, 70y, stool, N	Egypt	K Chl Tmp Nal CIP Azi	ST198/X1w	+	0.094	0.50	0.38	0.008	0.023	12	48	0.19	0.5
	Kentucky	28 Jan 11	F, 71y, stool, N		A Nal CIP Azi	ST198/X1w				0.75	0.5	0.19	8	32		0.50

507 ^aF, female; M, male; y, years (age); H, hospitalised; N, not hospitalised

508 ^bA, amoxicillin; Cro, ceftriaxone; Caz; ceftazidime; Fox, cefoxitin; IMP, imipenem (*, intermediate resistance according to CA-SFM, resistance according to CLSI); ETP, ertapenem; MEM,

509 meropenem; S, streptomycin; Sp, spectinomycin; K, kanamycin; T, tobramycin; N, netilmicin; G, gentamicin; Ak, amikacin; Is, isepamicin; Chl, chloramphenicol; Sul, sulfamethoxazole; Tmp,

510 trimethoprim; Nal, nalidixic acid; Cip, ciprofloxacin, Azi, azithromycin; CST, colistin; TGC, tigecycline

511 °CA-SFM and CLSI (M100 S22) breakpoints for carbapenems: IMP and MEM (CA-SFM, $S \le 2 \text{ mg/L}$, R > 8 mg/L, CLSI, $S \le 1 \text{ mg/L}$); ETP (CA-SFM, $S \le 0.5 \text{ mg/L}$, R > 1 mg/L;

512 CLSI, $S \le 0.5 \text{ mg/L}$, $R \ge 2 \text{ mg/L}$). For categorisation, Etest MICs between standard dilutions were rounded up to the next two-fold dilution

513 [¢]Isolate 09-9322 recovered by the French national surveillance system was also isolated from this single patient who had travelled to Egypt

515 516 Table 3: Mechanisms of resistance to antimicrobial drugs in the antimicrobial drug-resistant Salmonella isolates included in this study

10									
Isolate	Serotype			Main determinants of re	sistance to:				Class 1 integrons
		ESCs	Carbapenems	Cipr	ofloxacin		Azi	Aminoglycosides	
				GyrA	ParC	PMQR			
Isolates rec	covered through	the French national Salmonella	surveillance system						
09-8391	Kentucky	<i>bla</i> _{CMY-2} (IncI1, 90 kb)	-	Ser83Phe, Asp87Asn	Ser80Ile			-	-
09-9322	Kentucky	<i>bla</i> _{CMY-2} (IncI1, 90 kb; IncA/C, 200 kb)	-	Ser83Phe, Asp87Gly	Ser80Ile		mph(A) (NT)		1.8 kb (<i>dfrA12, aadA2</i>)
10-0720	Kentucky	<i>bla</i> _{CTX-M-1} (IncI1, 90 kb)	-	Ser83Phe, Asp87Asn	Ser80Ile		-		1.5 kb (<i>aacA5, aadA7</i>)
10-5456	Kentucky	<i>bla</i> _{CTX-M-15} (IncL/M, 90 kb)	-	Ser83Phe, Asp87Asn	Ser80Ile		mph(A) (NT)	armA (IncL/M, 90 kb)	1.8 kb (<i>dfrA12, aadA2</i>)
Isolates rec	covered through	the survey in Casablanca, Moro	ссо						
10-1923	Kentucky	-	<i>bla</i> _{VIM-2} (UT, 30 kb)	Ser83Phe, Asp87Gly	Ser80Ile		-		1.5 kb (aacA5, aadA7), 3 kb (aacA7, bla _{VIM-2} , aacC1, aacA4)
10-1922	Kentucky	-	<i>bla</i> _{VIM-2} (IncW, 30 kb)	Ser83Phe, Asp87Gly	Ser80Ile		-		1.5 kb (<i>aacA5</i> , <i>aadA7</i>), 3 kb (<i>aacA7</i> , <i>bla</i> _{VIM-2} , <i>aacC1</i> , <i>aacA4</i>)
10-1924	Kentucky	-	bla _{VIM-2} (IncW)	Ser83Phe, Asp87Gly	Ser80Ile		-		1.5 kb (aacA5, aadA7), 3 kb (aacA7, bla _{VIM-2} , aacC1, aacA4)
10-1925	Kentucky	-	<i>bla</i> _{VIM-2} (IncW)	Ser83Phe, Asp87Gly	Ser80Ile		-		1.5 kb (<i>aacA5</i> , <i>aadA7</i>), 3 kb (<i>aacA7</i> , <i>bla</i> _{VIM-2} , <i>aacC1</i> , <i>aacA4</i>)
10-1926	Kentucky	-	<i>bla</i> _{VIM-2} (IncW)	Ser83Phe, Asp87Gly	Ser80Ile		-		1.5 kb (<i>aacA5</i> , <i>aadA7</i>), 3 kb (<i>aacA7</i> , <i>bla</i> _{VIM-2} , <i>aacC1</i> , <i>aacA4</i>)
Isolates rec	covered from a s	ingle patient ¶							3.00 (IMP2), 1000 C , 1000 C /
09-7981	Saintpaul	-	<i>bla</i> _{OXA-48} (IncL/M, 70 kb)	WT	WT			-	-
10-0305	Kentucky	-	-	Ser83Phe, Asp87Gly	Ser80Ile		mph(A) (NT)		1.8 kb (<i>dfrA12, aadA2</i>)
11-0664	Kentucky	-	bla _{OXA-48} (NT)	Ser83Phe, Asp87Gly	Ser80Ile		mph(A) (NT)	-	-
7		LT						1	

NT, not transferable; UT, untypeable ^{\$}Isolate 09-9322 recovered by the French national surveillance system was also isolated from this single patient who had travelled to Egypt.




Figure 1. Human *S. enterica* serotype Kentucky isolates identified at the French National Reference Centre for *Salmonella* between 2000 and 2011

The total annual number of *S. enterica* serotype Kentucky isolates is indicated by a black triangle. The annual number of these isolates resistant to ciprofloxacin (CIP-R) is indicated in red, and that of isolates resistant to extended-spectrum cephalosporins (ESC-R) is shown in green. During this period, the total number of *Salmonella* spp. registered at the French National Reference Centre was 128,836 (2000, n=12,883; 2001, n=12,601; 2002, n=11,775; 2003, n=10,472; 2004, n=10,589; 2005, n=11,439; 2006, n=10,154; 2007, n=8,124; 2008, n=10,378; 2009, n=9,947; 2010, n=9,405; 2011, n=11,069).